Involvement of galanin and galanin receptor 2 in a mouse model of allergic rhinitis

DOI Web Site Web Site 参考文献26件 オープンアクセス
  • Kawada Michitsugu
    Department of Otorhinolaryngology, Kyorin University School of Medicine
  • Yokoi Hidenori
    Department of Otorhinolaryngology, Kyorin University School of Medicine
  • Kimura Toru
    Department of Pharmacology and Toxicology, Kyorin University School of Medicine
  • Matsumoto Yuma
    Department of Otorhinolaryngology, Kyorin University School of Medicine
  • Sakurai Hiroyuki
    Department of Pharmacology and Toxicology, Kyorin University School of Medicine
  • Matsumoto Kenji
    National Research Institute for Child Health and Development
  • Fujiwara Masachika
    Department of Pathology, Kyorin University School of Medicine
  • Saito Koichiro
    Department of Otorhinolaryngology, Kyorin University School of Medicine

この論文をさがす

抄録

<p>Background: Allergic rhinitis (AR) is caused by allergic reaction to allergens such as pollen. Galanin (GAL), a neuropeptide that regulates inflammatory processes, is widely expressed in the central and peripheral nervous systems. Although neuropeptides are implicated in arthritis and chemically induced ileitis, their roles in AR remain unclear.</p><p>Methods: We developed a murine model of AR and generated control, systemic sensitization, mild AR, and severe AR groups. We examined GAL and GAL receptor (GALR) mRNA and protein levels and localization patterns in each group using reverse transcription PCR, western blotting, and immunohistochemical analyses. Additionally, we evaluated the effects of M871, a GALR2 antagonist, on mice with severe AR.</p><p>Results: Gal and Galr2 are expressed in nasal mucosa and brain (control) samples from control and AR mice. GAL and GALR2 were expressed at similar levels and localized to ciliated epithelial and submucosal gland cells of the nasal mucosa in all four groups. Intranasal M871 administration significantly reduced the incidence of nose rubbing behaviors and sneezing (p < 0.001 in 30 min, respectively) in severe AR mice relative to that in controls. Mechanistically, we postulate that GALR2 is expressed in B cells, and M871 administration reduces IgE production, as well as the number of B cells in tissues.</p><p>Conclusions: GAL signaling may not change progressively with increasing nasal sensitization, suggesting that this signaling process exacerbates, rather than directly trigger, AR. GAL-GALR2 signaling likely mediates AR development, suggesting that its inhibition represents a novel therapeutic strategy for AR.</p>

収録刊行物

参考文献 (26)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ